Firm-Wide blog

FDA Warns IBS Drug Viberzi is Associated with an Increased Risk of Pancreatitis For Patients Without a Gallbladder

On March 15, 2017, FDA issued a Drug Safety Communication, warning that patients without a gallbladder who are prescribed the drug Viberzi (eluxadoline) face an increased risk of serious pancreatitis that could result in hospitalization or death. Viberzi is a medicine that is used to treat irritable bowel syndrome with diarrhea (IBS-D).  A recent FDA […]

Free case evaluation form